OBJECTIVES: To investigate possible associated pathology in the prostate removed from patients with invasive bladder cancer and determine if there is a justification for prostate-sparing cystectomy. PATIENTS AND METHODS: Between March 2005 and July 2007, 425 men (mean age 59 years, sd 8.23) had a cystoprostatectomy at our institute. The prostate was step sectioned at 2-3 mm intervals and any associated pathology determined; patient and tumour characteristics were correlated with prostatic pathology. The results were compared with those published previously, and the potential functional advantages of prostate sparing are reviewed and discussed. RESULTS: Prostatic adenocarcinoma was detected in 90 of the 425 (21.2%) patients. There was no significant correlation between preoperative prostate-specific antigen level and the presence of adenocarcinoma, Gleason score or prostatic tumour stage. There was prostatic involvement as a result of direct invasion by the primary bladder tumour (contiguous) in 39 cases (9.2%). Concomitant (non-contiguous) transitional cell carcinoma of the prostatic urethra and/or ducts was detected in 27 specimens (6.4%). Additional findings were high-grade prostatic intraepithelial neoplasia in 43 patients (10.1%) and benign prostatic hyperplasia in 175 (41.2%). CONCLUSION: We think that the potential oncological risks of prostate-sparing cystectomy outweigh any small and possible functional benefits; accordingly, the prostate should not be retained.
OBJECTIVES: To investigate possible associated pathology in the prostate removed from patients with invasive bladder cancer and determine if there is a justification for prostate-sparing cystectomy. PATIENTS AND METHODS: Between March 2005 and July 2007, 425 men (mean age 59 years, sd 8.23) had a cystoprostatectomy at our institute. The prostate was step sectioned at 2-3 mm intervals and any associated pathology determined; patient and tumour characteristics were correlated with prostatic pathology. The results were compared with those published previously, and the potential functional advantages of prostate sparing are reviewed and discussed. RESULTS:Prostatic adenocarcinoma was detected in 90 of the 425 (21.2%) patients. There was no significant correlation between preoperative prostate-specific antigen level and the presence of adenocarcinoma, Gleason score or prostatic tumour stage. There was prostatic involvement as a result of direct invasion by the primary bladder tumour (contiguous) in 39 cases (9.2%). Concomitant (non-contiguous) transitional cell carcinoma of the prostatic urethra and/or ducts was detected in 27 specimens (6.4%). Additional findings were high-grade prostatic intraepithelial neoplasia in 43 patients (10.1%) and benign prostatic hyperplasia in 175 (41.2%). CONCLUSION: We think that the potential oncological risks of prostate-sparing cystectomy outweigh any small and possible functional benefits; accordingly, the prostate should not be retained.
Authors: Mamatha Damodarasamy; Robert B Vernon; Christina K Chan; Stephen R Plymate; Thomas N Wight; May J Reed Journal: In Vitro Cell Dev Biol Anim Date: 2014-08-15 Impact factor: 2.416
Authors: Rafal Turo; Michal Smolski; Umi Hatimy; Stephen J Bromage; Stephen C W Brown; Richard Brough; Gerald N Collins Journal: Can Urol Assoc J Date: 2014 Mar-Apr Impact factor: 1.862
Authors: Maria M Rivera Del Alamo; Mireia Díaz-Lobo; Silvia Busquets; Joan E Rodríguez-Gil; Josep M Fernández-Novell Journal: Biochem Biophys Rep Date: 2018-04-02